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ABSTRACT
A simple and accurate method for the determination of chloroquine diphosphate (CQ), pyrimethamine (PYM) and trimethoprim
(TMP) in pure, pharmaceutical and urine samples is described. The method involved an ion pair extraction procedure with chloroform using an acid base indicator, bromocresol purple (BCP), as a counter ion. The ion pair extracted in organic phase was yellow,
and the absorbance was measured at λ max = 420 nm. Beer’s law was obeyed over the concentration range of 1.25-8.75, 0.62-7.5,
and 1.25-10.71 μg/mL, respectively. The Sandell’s sensitivity was 0.01258, 0.01102 and 0.01464 μg/cm 2. The Ringbom optimum
concentration range, which was 2.5-7.5, 1.25-7.5 and 2.5-10.7 μg/mL for CQ, PYM, and TMP, respectively, exhibited reliability of
the method. Stoichiometry and thermodynamic of the complexes were evaluated by Job’s method and Benesi-Hildebrand plot. The
statistical results of intra- and inter-day estimation of drugs and comparison with the reported methods demonstrated high precision
and accuracy of the method. The procedure was rapid, simple and suitable for quality control purpose.
Key words: ion pair complex, bromocresol purple, chloroquine diphosphate, pyrimethamine, trimethoprim

INTRODUCTION
Malaria, which was nearly wiped out on the 60’s, is
reemerging as the top infectious killer and is currently
the highest priority tropical disease of the World Health
Organisation (WHO). It is caused by erythrocytic forms
of Plasmodium vivax, P. ovale, P. malariae, and P. falciparum, preferentially affecting children younger than 5
years of age, pregnant women, and non-immune individuals (1). CQ, PYM and TMP are blood schizontocides(1,2),
acting on the blood form of the parasite and thereby
terminating clinical attack of Malaria.
CQ, a quinoline-based drug, is highly effective and
has been the mainstay of antimalarial chemotherapy.
However, the presence of CQ-resistant Malaria has been
widely reported. CQ acts by preventing heme polymerization, which kills the parasite via oxidative damage
to their critical biomolecules (1). CQ is also used in
arthritis (3) and cancer treatment (4-6).
The major role of diaminopyridine drugs, PYM and
TMP, has been attributed to their ability to block the
synthesis of tetrahydrofolate by inhibiting dihydrofolate
* Author for correspondence. Tel: +91-821-2412557;
Fax: +91-821-2421263; E-mail: profpn58@yahoo.com

reductase (1,7). PYM is recommended for use as a suppressive treatment in CQ-resistant area. The drug is always
given with a sulfonamide or sulfone (1). TMP along with
sulfamethoxazole, commonly known as co-trimoxazole,
a widely used antibacterial agent, is used as a prophylaxis
especially in HIV patients (8).
Various methods have been reported for the quantification of these drugs. CQ is analysed by LC/MS(9), HPTLC(10),
HPLC(10,11), and spectrophotometric methods(12-14). PYM
is determined by LC/MS(15), HPLC(16,17), and spectrophotometric methods(12,18,19). TMP is estimated by HPLC(20),
voltammetric(21) and spectrophotometric methods(22-25).
In this study, we have explored the use of Bromocresol
Purple (BCP), a sulfonephthalein indicator, to establish a
simple, reliable, and rapid method for the estimation of these
drugs in pure, and pharmaceutical products. The method
was also applied in human urine samples as the concentration range that can be estimated by the proposed method
lies within the range discussed for CQ(26), PYM(27,28), and
TMP(24,29), mainly during the treatment of the patient with
acute infection, when the dosage administered is high(30). In
addition, the association constant, molar ration of reactant,
and free energy change were also determined.
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I. Apparatus
A JASCO (Model UVIDEC-610) UV/VIS spectrophotometer with 1 cm-matched glass cell was used for all
absorbance measurements.
II. Reagents and Solutions
All chemicals used were of analytical grade; twice
distilled water was used throughout the experiment. BCP,
CQ, TMP and PYM were obtained from Sigma-Aldrich
Co (St. Louis, USA).
(I) Preparation of BCP

of BCP. The reaction mixtures were extracted with
5 mL of chloroform by shaking for 40 seconds at vortex.
One milliliter of the organic layer was diluted to 10 mL
with chloroform in volumetric flasks. The absorbance of
yellow-colored extracts was measured at 420 nm against
corresponding blank solutions. All measurements were

(A)

A 200 μg/mL BCP solution was prepared by
dissolving 20 mg of BCP in 100 mL of 10% ethanol.

CHCl3

0.3

0.2

0.1

(II) Preparation of Standard Solution
Stock solutions of 200 μg/mL CQ were prepared in
water. The same concentration of PYM and TMP were
prepared in 10% ethanol. The solutions were further diluted
quantitatively according to their linear calibration range.

CQ-BCP in CHCl3
0.4
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(IV) Preparation of Urine Samples
Drug-free human urine samples were collected
from healthy volunteers and stored in a freezer at -20℃.
Urine samples were centrifuged for 5 min, and the clear
supernatants were used as stock sample solutions. Stock
solutions were spiked with suitable quantity of drugs to
prepare urine containing 200 µg/mL of drugs.
III. Methods
(I) Standard Procedure for the Determination of Drugs
Aliquots of 0.31-2.2 mL of CQ, 0.15-1.87 mL of
PYM, and 0.31-2.67 mL of TMP were transferred from
standard stock solutions into a series of 10-mL stoppered flasks, followed by addition of 1.5 mL of acetic
acid/sodium acetate buffer (0.1 M) of pH 4.5 and 2 mL
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TMP-BCP in CHCl3
CHCl3
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Twenty tablets of each drug were weighed and finely
powdered using mortar and pestle. A quantity equivalent to 20 mg of each drug was transferred to 100-mL
volumetric flasks to prepare 200 µg/mL solutions. The
mixtures were shaken mechanically with water for 5 min,
sonicated in an ultrasonic bath for 30 min, diluted to the
volume, mixed and filtered. Appropriate aliquots of the
filtrates were further diluted with water to obtain the
required concentrations.

Absorbance

(III) Preparation of Tablet Sample Solution
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Figure 1. Absorption spectra of (A) CQ (5.0 µg/mL), (B) PYM (3.75
µg/mL), and (C) TMP (5.0 µg/mL).
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made at room temperature (25 ± 1°C). The calibration
curves were prepared by plotting absorbance versus
concentration of the respective drugs.
(II) Application of the Proposed Method to Pharmaceutical
Formulations
The recoveries of the drugs were examined by standard addition method by transferring a known quantity
to standard flasks. When the standard solutions with suitable concentrations of drugs were added, the concentrations fell within the respective linear calibration range,
except in one. The solutions were treated as mentioned in
the “standard procedure section.”
(III) Application of the Proposed Method to the
Determination of Drugs in Spiked Human Urine
The recovery study was carried out in urine samples

(A)

O

Br

I. Spectral and Elemental Characterization
The method was based on the ion transfer complex
formed by BCP, an acidic dye, and drugs that have basic
nitrogen as electron donor to yield ion-pair salts which
form color compound extractable from the aqueous
solution to organic phase. The absorbance spectra and
proposed reaction mechanism are shown in Figure 1 and
Scheme 1.
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by standard addition method. As mentioned above,
spiked urine in three different concentrations were transferred to a series of standard flasks. Different amounts
of drugs were added from the standard stock solution,
causing the total concentration fell within the Beer’s law
range.
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Scheme 1. Proposed reaction mechanism of (A) CQ-BCP, (B)
PYM-BCP, (C) TMP- BCP.
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II. Optimization of Reaction Variables

0.781 for PYM : BCP and 0.640 : 0.618 for TMP : BCP
which further confirmed the complex ratio at 1 : 2, 1 : 1
and 1 : 1 respectively.

(I) Concentration of BCP
The effect of dye concentration on the intensity of
the color developed was tested using different amounts of
BCP. The result showed that 1 mL of BCP was optimum
for this method.
(II) Effect of pH Buffer
A variable relationship between the absorbance at
420 nm and the pH for CQ, PYM and TMP, which was
studied in the range of 3-5.5 using acetic acid/sodium
acetate buffer (0.1 M), indicated that the reactions took
place at optimum pH of 4.5 (Figure 2).
(III) Selection of Extraction Solvent
The effect of extracting solvent on the ion pair
complex was studied in two organic solvents, dichloromethane and chloroform. Chloroform was selected
because of its high color intensity.
(IV) Optimization of Shaking Time
Shaking times of 10 seconds to 2 minutes were
studied. The optimum shaking time was fixed at 40
seconds.
(V) Stoichiometric Relationship
The combination ratio was evaluated by the Job’s
method of continuous variation (Figure 3), which shows
that the complex formed between the drugs, CQ, PYM,
and TMP, and BCP were 1 : 2, 1 : 1 and 1 : 1 respectively. The plot of log absorbance against log BCP and
the drugs in limiting logarithmic method (Figure 3)
shows the slope of 0.459 : 0.232 for CQ : BCP; 0.782 :
0.4
a

0.35
0.3

Absorbance

b
0.25
0.2

c

The association constants were calculated for the
interaction of each drug with BCP using Benesi-Hildebrand equation:
1
1
Ao
=
+
ε
A
K ε D0

where, A0 and D 0 are the initial concentration of
the acceptor and the donor, respectively. ε is the molar
absorptivity of the complex and K is the association
constant. The standard free energy changes of complex
(ΔG 0) were calculated from the association constant by
the following equation:
ΔG0 = -2.303RTlogK
where, R is Gas constant, and T is the temperature in Kelvin. A straight line was obtained by plotting
the value of A0/A against 1/D (Figure 4). The intercept
of line with the ordinate is 1/ε and the slope equal to
1/K ε. The molar absorptivity was 42424, 21192, and
20608 L/mol·cm for CQ, PYM, and TMP, respectively,
which correlated with the value obtained from linear
calibration curve. The association constant (K) was 3981,
5225, and 4332 M-1, and the standard free energy, ΔG 0,
was -4.90, -5.07, and -4.96 kcal for CQ, PYM, and TMP,
respectively.
III. Method Validation
(I) Linearity, Detection and Quantification Limits
The Beer’s law range, molar absorptivity, sandell’s
sensitivity, regression equation, and correlation coefficient were determined for each drug. A linear relationship was found within the range of 1.25-8.75 µg/mL for
CQ, 0.625-7.5 µg/mL for PYM, and 1.25-10.7 µg/mL
for TMP. Regression analysis of the Beer’s Law plots
revealed strong correlation. The graph showed a negligible intercept, which was calculated by the least-square
method’s regression equation:
A = a + bc,

0.15
0.1
0.05
0

(VI) Association Constants and Standard Free Energy
Changes

3.5

4

4.5

5

5.5

pH

Figure 2. Effect of pH on the formation of complex between BCP and
(a) CQ (5 µg/mL), (b) PYM (2.5 µg/mL) and (c) TMP (2.5 µg/mL).

where, A is the absorbance of solution in a 1-cm cell,
a is the intercept, b is the slope, and c is the concentration of the measured solution in µg/mL. The high molar
absorptivity of the resulting colored solution indicated
high sensitivity of the method. The limit of detection
(LOD) and the limit of quantification (LOQ) value were
determined using the formula:
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LOD or LOQ = К SD/b
where К = 3 for LOD and 10 for LOQ. SD is standard deviation of the response of the blank solution and
b is slope of calibration curve. The Ringbom plot demonstrated the range of 2.5-7.5, 1.25-7.5, and 2.5-10.7 µg/mL

0.25

for CQ, PYM, and TMO, respectively as indicated on
Table 1. The confidence limits for the slope of line of
regression and intercept were computed using the relation, b ± tSb and a ± tSa at 95% confidence level. The
results are shown in Table 1.
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Figure 3. Job’s method of continuous variation plots and Limiting logarithmic plots for the molar reactivity for (A) CQ , CQ and BCP = 4.85
× 10 -5 M, a = Slope for CQ, b = Slope for BCP; (B) PYM, PYM and BCP = 1.0 × 10 -4 M, c = Slope for PYM, d = Slope for BCP; (C) TMP, TMP
and BCP = 8.6 × 10 -5 M, e = Slope for TMP, f = Slope for BCP.
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concentration of drugs was defined by the expression:
2

( yo − y )
Sy/x  1
Sc =
1+ +
b  n b 2 ( x − x)
∑




2



where ȳ and x̄ are the average values of the absorbance and
concentration for n standard samples, respectively. Figure 5
shows the graph of the error, Sc vs. concentration of respective drugs. Minimum error was reached at absorbance of 5,
3.75, and 5 µg/mL of CQ, PYM, and TMP, respectively.

0.00045

(II) Interference Study

1/ 2

The effect of common excipients used in the pharmaceutical preparation was studied by analyzing
synthetic sample solutions containing the quantity
of drugs as mentioned on Table 2 with 100-fold more
concentration of each excipient. For sulfadoxine and
sulfamethoxazole, the study was carried out at 200 times
the concentration of PYM and TMP, respectively. The
tolerance limit was the concentrations that gave an error
of ± 3.0% in the determination of drugs. The results indicated that the excipients studied did not interfere with the
quantitative analysis by the present method. The sample
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Figure 4. Benesi-Hildbrand plots for (A) CQ-BCP, (B) PYM-BCP,
and (C) TMP-BCP.
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Figure 5. Plots of error in the determination of CQ, PYM, and TMP.
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Table 1. Optical characteristics and statistical data of the regression equation for the reaction of the proposed method
Optical characteristic

Parameters
Colour
λmax (nm)
Beer’s Law range (μg/mL)

CQ

PYM

TMP

Yellow

Yellow

Yellow

420

420

420

1.25-8.75

0.62-7.5

4

1.25-10.71
4

Molar absorptivity (L/mol·cm)

4.09 × 10

2.25 × 10

1.98 × 104

Sandell’s sensitivity (μg/cm2)

0.01258

0.01102

0.01464

Limit of Detection (μg/mL)

0.128

0.107

0.154

Limit of Quantification (μg/mL)

0.428

0.356

0.513

Ringbom optimum concentration range (μg/mL)

2.5-7.5

1.25-7.5

2.5-10.7

Slope (B)

0.0793

0.0950

0.0662

Intercept (A)

-0.0026

-0.0134

0.0106

0.9989

0.9998

0.9991

a

Regression Equation (Y)

Correlation Coefficient(r)
b

0.27

Relative standard deviation
c

3.05 × 10

± tSb

± tSad

0.136
-3

0.902
-3

5.05 × 10-3

1.82 × 10

0.0172

8.05

0.0325

a

Y = Bx + A, where x is the concentration of the measured solution in µg/mL.
Average of six determinations (concentration of 5, 3.75 and 5 μg/mL of pure drugs of CQ, PYM, and TMP respectively).
c
Confidence Interval for Slope at 95% confidence limit for five degree of freedom.
d
Confidence Interval for Intercept at 95% confidence limit for five degree of freedom.
b

Table 2. Recovery of drugs from solutions with a 100 fold concentration of various additives* present
Excipients

Recoverya ± S.D
CQb

PYMc

Dextrose

100.00 ± 0.02

100.02 ± 0.05

99.91 ± 0.05

Lactose

100.00 ± 0.07

99.90 ± 0.06

100.93 ± 0.05

Starch

99.10 ± 0.03

99.84 ± 0.03

99.81 ± 0.10

Sucrose

99.91 ± 0.03

99.85 ± 0.03

100.10 ± 0.07

Carboxymethyl cellulose

99.82 ± 0.04

100.21 ± 0.07

99.96 ± 0.03

100.04 ± 0.05

99.90 ± 0.06

99.60 ± 0.06

99.40 ± 0.10

100.04 ± 0.03

100.11 ± 0.07

100.08 ± 0.02

100.04 ± 0.04

100.05 ± 0.10

Talc
Magnesium Sterate
Sodium Chloride
Sulfadoxine*

100.02 ± 0.02

Sulfamethoxazole*
Urea

a

TMPd

99.91 ± 0.02
100.00 ± 0.01

100.00 ± 0.10

100.03 ± 0.03

Creatinine

99.90 ± 0.02

99.86 ± 0.10

99.90 ± 0.07

Bovine serum albumin

99.91 ± 0.02

99.94 ± 0.08

99.75 ± 0.03

 ean of 3 determinations.
M
b
Concentration of CQ used - 5 μg/mL.
c
Concentration of PYM used - 3.75 μg/mL.
d
Concentration of TMP used - 5 μg/mL
* Concentrations of additives taken were 200 times more.
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containing bovine serum albumin (BSA) was allowed to
stand for 30 min before measuring the absorbance.
(III) Precision and Accuracy
The short-term precision (intra-day precision) of
the drugs was evaluated by measuring 5 independent
samples at 3 different concentration levels (2.5, 3.75,
5.0 µg/mL for CQ, 1.25, 2.5, 3.75 µg/mL for PYM, and
3.75, 5.0, 6.25 µg/mL for TMP). Similarly, the assay for

Table 3. Intraday and interday precision data
Amount Taken
Intraday
Intraday
(μg/mL)
(%Recovery ± S.Da) (%Recovery ± S.Db)
CQ

PYM

TMP

a
b

2.5

99.92 ± 0.09

99.81 ± 0.09

3.75

100.04 ± 0.09

99.91 ± 0.09

5.0

100.06 ± 0.04

100.05 ± 0.08

1.25

99.95 ± 0.05

99.62 ± 0.07

2.5

100.05 ± 0.02

99.84 ± 0.07

3.75

100.06 ± 0.03

99.91 ± 0.07

3.75

100.04 ± 0.05

99.63 ± 0.08

5.0

100.02 ± 0.04

99.96 ± 0.06

6.25

100.07 ± 0.06

99.50 ± 0.05

Mean of 5 determinations
Mean of 5 determinations performed over a period of 5 days

daily precision (inter-day precision) at the same concentration level was repeated for 5 consecutive days. The
standard deviations for the intra-day and inter-day assays
were between 0.02 - 0.09 and 0.05 - 0.09, respectively,
indicating good precision of the proposed method. The
results are presented in Table 3.
The proposed method was applied to estimate drugs
in pharmaceutical formulations. Precision of the method
was checked by taking six replicate measurements.
The results were compared statistically with reference
methods. The standard deviation of the labeled amount
ranged between 0.07 and 0.09. Student’s t- values ≤ 2.44
for pharmaceutical samples at the 95% confidence limits
indicated insignificant difference between the proposed
and the reported methods. Analytical results measured
for the same pharmaceuticals by the proposed and reference methods were compared using F-test. F-values
≤ 5.05 indicated insignificant difference in precision
between both methods at 95% confidence interval. Reliability and accuracy of the proposed method were further
ascertained through recovery studies using the standard
addition method by adding different amounts of standard
drugs to the pre-analyzed dosage forms such that the
cumulative amount did not exceed their linearity range.
The mean percentage recoveries, relative to the labeled
amounts ranged from 99.71 (± 0.21) to 99.99 (± 0.15).
Similarly, the recovery study in urine at three different
concentration ranges by standard addition method was
carried out. The excellent recoveries illustrated absence
of interference from the matrix effect in the urine
samples. The results are shown on Tables 4 and 5.

Table 4. Analysis of drugs in pharmaceutical formulations
Formulation
Emquinc

Labelled (mg)

Proposed method ± S.D (mg)a

Reported Method ± S.D(mg)a*

%Recovery ± R.S.Db

250

249.96 ± 0.09

250.01 ± 0.10[18]

99.97 ± 0.21

24.8 ± 0.09[18]

99.71 ± 0.19

79.90 ± 0.11[23]

99.99 ± 0.15

F = 1.23
t = 0.92
Amalard

25

24.90 ± 0.07
F = 1.65
t = 2.17

Septran

e

80

80.01 ± 0.09
F = 1.49
t = 1.88

a

 verage ± standard deviation of six determinations; the t- and F- values obtained after comparison to the reference methods have following
A
theoretical values at 95% confidence limits; t = 2.44 F = 5.05
b
After adding four different amounts of pure drugs to the fixed concentration of preanalysed pharmaceutical formulations.
c
CQ equivalent to 250 mg/tablet (E-Merck, India)
d
PYM equivalent to 25 mg/tablet (Alimbic, India)
e
TMP equivalent to 80 mg/tablet (GSK, India)
* Numbers inside the bracket indicate reference number of the reported methods given under References Section.
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Table 5. Analysis of drugs in urine
Drug

Drug added (μg/mL)

Drug Found (μg/mL) ± SD

CQ

3

3.01 ± 0.02

4

3.99 ± 0.01

5

5.01 ± 0.07

2

1.99 ± 0.02

3

3.00 ± 0.02

4

4.01 ± 0.03

3

2.98 ± 0.05

4

3.99 ± 0.02

5

5.02 ± 0.08

PYM

TMP

CONCLUSIONS
The recommended method using BCP for the analysis of the drugs is simple, inexpensive sensitive and
accurate. The optical parameters and statistical comparison have justified application of this method in routine
drug estimation in pure and dosage forms. Furthermore,
the procedure does not involve any critical reaction
conditions or tedious sample preparation steps. Therefore, this method can be recommended for routine analysis of these drugs.
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